DataM Intelligence unleashes a new market report titled ‘Global Alopecia Medication Market – Size, Share and Forecast (2019-2026)’

Alopecia Medication Market Dynamics
According to the National Alopecia Areata Foundation, Alopecia areata is a common autoimmune disease that occurs in males and females of all ages and races, but onset most often occurs in childhood and approximately 147 million worldwide have or will develop alopecia areata at some point in their lives. The global Alopecia Medications market is primarily driven by the high prevalence of the Alopecia worldwide.
A meta-analysis study suggests that androgenetic alopecia, a genetically predetermined disorder due to excessive response to androgens, affects up to 50% of males and females.
Various launch, approvals, and pipeline of alopecia medications products are expected to drive the growth of the market.

Alopecia Medication Segmentation
By Alopecia type, the global Alopecia market is segmented into androgenic alopecia, alopecia areata, cicatricial alopecia, traction alopecia, and alopecia totalis.
By Drug type, the global Alopecia market is segmented into minoxidil, finasteride, corticosteroids, immunosuppressants (cyclosporine, and others).
By Gender, the global Alopecia market is segmented into male and female.
According to American Hair Loss Association (AHLA) by the age of 35, two-thirds of American men will experience some degree of appreciable hair loss.

Alopecia Medication Market Geographical Share
North America holds the dominant share of the global Alopecia Medications market, and it is primarily attributed to factors such as due to the rise in the prevalence of hair loss and subsequently the increasing demand for its medications.
According to the National Alopecia Areata Foundation, Alopecia areata affects as many as 6.8 million people in the U.S. with a lifetime risk of 2.1%. The United States and Canada have a major influence on the regional market of North America.

Alopecia Medication Companies
Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. Regulatory approvals along with increased focus on R&D are other ways the leading players improve their market presence.
March 2019, Concert Pharmaceuticals announced that it initiates an open-label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trials are intended to inform the optimal dosing regimen for CTP-543 for future clinical trials.

Head to this space to collect a free sample market research report-
https://www.datamintelligence.com/research-report/alopecia-medication-market/

Contents of the research report are-

1. Alopecia Medication Market Scope and Methodology
1.1. Research Methodology
1.2. Scope of the market

2. Alopecia Medication Industry Trends
2.1. Key Trends and Developments

3. Alopecia Medication Market Outlook
3.1. Drivers
3.2. Restraints
3.3. Supply Chain Analysis
3.4. Epidemiology
3.5. Key Developments

4. Alopecia Medication Market Segmentation Analysis
4.1. By Alopecia Type
4.1.1. Androgenic Alopecia
4.1.2. Alopecia Areata
4.1.3. Ciatricial Alopecia
4.1.4. Traction Alopecia
4.1.5. Alopecia Totalis
4.2. By Drug Type
4.2.1. Minoxidil
4.2.2. Finasteride
4.2.3. Corticosteroids
4.2.4. Immunosuppressants
4.2.4.1. Cyclosporine
4.2.4.2. Others
4.3. By Route of Administration
4.3.1. Oral
4.3.2. Topical
4.3.3. Injectable
4.4. By Gender
4.4.1. Males
4.4.2. Females
4.5. By Distribution Channel
4.5.1. Hospitals
4.5.2. Retail Pharmacies
4.5.3. Online Pharmacies

5. Regional, Country-level Analysis
5.1. Geographic Overview
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.2.3. Mexico
5.3. Europe
5.3.1. Germany
5.3.2. U.K.
5.3.3. France
5.3.4. Rest of Europe
5.4. South America
5.4.1. Brazil
5.4.2. Argentina
5.4.3. Rest of South America
5.5. Asia Pacific
5.5.1. China
5.5.2. India
5.5.3. Japan
5.5.4. Australia
5.5.5. Rest of Asia Pacific
5.6. Rest of World

6. Alopecia Medication Market Competitive Analysis
6.1. Competitive Scenario
6.2. Key Strategies adopted by Manufacturers
6.3. Product Benchmarking

7. Alopecia Medication Market Company Profiles
7.1. Histogen, Inc.
7.2. Aclaris Therapeutics, Inc.
7.3. Concert Pharmaceuticals, Inc.
7.4. HCell Inc.
7.5. GlaxoSmithKline plc.
7.6. Daiichi Sankyo, Inc.
7.7. Cipla Limited

8. Alopecia Medication Market Appendix
8.1. Sources
8.2. List of Tables
8.3. Expert Panel Validation
8.4. Disclaimer
8.5. Contact Us

About DataM Intelligence

DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

Market Research for long has been losing its credibility owing to low reliability and high proportions of estimations. Having identified this gap, DataM was established to provide businesses with reliable and near-market intelligence. Reporting the actual market scenario has been made possible by our proprietary methodology, that essentially revolves around gathering inputs from industry participants and integrating the trends into statistical Databank. This approach not only aligns the findings with historic data but also allows a highly justifiable forecast model.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery and Automation among others.

Sai Kiran
sales@datamintelligence.com

1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

This release was published on openPR.